Denosumab (anti-RANK ligand)

Catalog No.A2020 Synonyms: AMG-162, Prolia, Xgeva

For research use only.
Not for use in humans.

Denosumab (anti-RANK ligand) (AMG-162, Prolia, Xgeva) is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL (143–317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM.

Quality Control

Choose Selective NF-κB Inhibitors

Biological Activity

Description Denosumab (anti-RANK ligand) (AMG-162, Prolia, Xgeva) is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL (143–317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM.

Protocol

Product Details

CAS No. 615258-40-7
Formulation PBS Buffer, pH 7.4
Isotype human IgG4
Source HEK293
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

NF-κB Signaling Pathway Map

Related NF-κB Products

Tags: buy Denosumab (anti-RANK ligand) | Denosumab (anti-RANK ligand) supplier | purchase Denosumab (anti-RANK ligand) | Denosumab (anti-RANK ligand) cost | Denosumab (anti-RANK ligand) manufacturer | order Denosumab (anti-RANK ligand) | Denosumab (anti-RANK ligand) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID